Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tg100-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG known ✓ | P48736 | 13/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PDXK | O00764 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | OXSR1 | O95747 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tg100-115 SCHEMBL29506727 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL31238338 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29369340 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29361550 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29411790 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539255 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3537211 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539251 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL13403357 | 0.92 | PIK3CG (0.85) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3743017 | 0.91 | PIK3CG (0.82) | PIK3CGPIK3CAPIK3CBMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | claimed |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | claimed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | claimed |
| EP-2254581-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TargeGen, Inc. (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009100305-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2009-08-13 | — | — | WO | claimed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | claimed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | claimed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585268-A2 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Twelve Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-3350183-B1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-3377068-B1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4438734-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240317763-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240293415-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11939333-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220387491-A1 | METHODS OF MAKING CELLULAR THERAPIES | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2022-12-08 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3474856-B1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220241287-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220125794-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | disclosed |
| WO-2022040606-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-02-24 | — | — | WO | disclosed |
| US-11247995-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | disclosed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11191770-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-20210338681-A1 | COMBINATION THERAPIES | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2021-11-04 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11147818-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-11110096-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860609-A1 | COMBINATION THERAPIES | Secura Bio, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210113584-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2021-04-22 | — | — | US | disclosed |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10934528-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10857156-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2020-12-08 | — | — | US | disclosed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200338083-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020072445-A1 | COMBINATION THERAPIES | VERASTEM, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| EP-2791101-B1 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | VASCULAR BIOGENICS LTD (IL) | 2019-09-18 | — | — | EP | disclosed |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2019-07-25 | — | — | US | disclosed |
| US-20190216816-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190185477-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308912-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3474856-A1 | COMBINATION THERAPIES | Infinity Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2019035008-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| US-10160761-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | INFINITY PHARMACEUTICALS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3399026-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3377068-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | Senhwa Biosciences, Inc. (TW) | 2018-09-26 | — | — | EP | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| EP-2580320-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3350183-A1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Infinity Pharmaceuticals, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2018-06-28 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180055847-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2017223422-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170348314-A1 | COMBINATION THERAPIES | HCR COLLATERAL MANAGEMENT, LLC | 2017-12-07 | — | — | US | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| CN-106905297-A | For the novel therapeutic agents of the cancer of the brain | 加利福尼亚大学董事会 | 2017-06-30 | — | — | CN | disclosed |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2017-06-08 | — | — | US | disclosed |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2017-05-25 | — | — | US | disclosed |
| US-20170088553-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2017048702-A1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-9556417-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3119397-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016209688-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016193955-A1 | COMBINATIONS OF KINASE INHIBITORS FOR TREATING COLORECTAL CANCER | STASSI GIORGIO (IT) | 2016-12-08 | — | — | WO | disclosed |
| US-20160264938-A1 | Reprogramming of Cells to a New Fate | THE SCRIPPS RESEARCH INSTITUTE | 2016-09-15 | — | — | US | disclosed |
| WO-2016127455-A1 | PYRIMIDINE DERIVATIVE, CYTOTOXIC AGENT, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 南京盖特医药技术有限公司 | 2016-08-18 | — | — | WO | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-9376664-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
| EP-3024457-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-3024456-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2015-11-12 | — | — | US | disclosed |
| US-20150320755-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2015160975-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160986-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015143012-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-09-17 | — | — | US | disclosed |
| US-20150254400-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-10 | — | — | US | disclosed |
| EP-2898103-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | Agency For Science, Technology And Research (SG) | 2015-07-29 | — | — | EP | disclosed |
| EP-2861588-A2 | NOVEL THERAPEUTICS FOR BRAIN CANCER | The Regents of The University of California (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-2791101-A1 | TREATMENT OF INFLAMMATION | Vascular Biogenics Ltd. (IL) | 2014-10-22 | — | — | EP | disclosed |
| US-8853235-B2 | Polymorphs and salts of a kinase inhibitor | SENHWA BIOSCIENCES, INC. (TW) | 2014-10-07 | — | — | US | disclosed |
| WO-2014046619-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014031856-A1 | COMBINATION THERAPY USING PI3 KINASE AND BRAF INHIBITORS | ONCONTHYREON INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| WO-2013188813-A2 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | WO | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20130280809-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2013147649-A2 | INHIBITORS OF THE PI3K/AKT/IKK/NF-KB SIGNALLING PATHWAY, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND COMPOSITIONS CONTAINING SAID INHIBITORS FOR THE PROPHYLAXIS AND TREATMENT OF VIRAL DISEASES | ХОЛИН, Максим Николаевич (RU) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013088245-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | WO | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| EP-2580320-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012120048-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2012-09-13 | — | — | WO | disclosed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012118978-A1 | METHODS FOR TREATING ONCOVIRUS POSITIVE CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-2477493-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| EP-2475652-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | Cylene Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2456441-A1 | COMBINATION THERAPIES WITH CK2 MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120129849-A1 | DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012054493-A1 | DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2411003-A1 | USE OF ARTEMISININ DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | National University of Singapore (SG) | 2012-02-01 | — | — | EP | disclosed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011159726-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011035019-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| CN-101983060-A | Methods and compositions for treating respiratory disease | TARGEGEN INC | 2011-03-02 | — | — | CN | disclosed |
| WO-2011011199-A1 | COMBINATION THERAPIES WITH CK2 MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2254581-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TargeGen, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254581-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TargeGen, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278837-A1 | Compositions And Methods For Reducing Cancer And Inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010110747-A1 | USE OF ARTEMISININ DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2010-09-30 | — | — | WO | disclosed |
| US-20100135900-A1 | CD37 IMMUNOTHERAPEUTIC COMBINATION THERAPIES AND USES THEREOF | TRUBION PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2009100305-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100305-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100305-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TARGEGEN INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007127366-A2 | KINASE INHIBITORS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127366-A2 | KINASE INHIBITORS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1720224-A | Vascular balancing agents and methods of use thereof | TARGEGEN INC (US) | 2006-01-11 | — | — | CN | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20150320755-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CG 30/4885PIK3CD 29/4885PIK3CA 24/4885 |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | CD14, TLR2, TLR4 | PIK3CG 1910/4885PIK3CD 1641/4885PIK3CA 2517/4885 |
| US-11191770-B2 | — | CXCR4, TLR7, CCR7 | PIK3CG 2984/4885PIK3CD 2949/4885PIK3CA 1413/4885 |
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20170088553-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20150259326-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | PIK3CG 2706/4885PIK3CD 3305/4885PIK3CA 3408/4885 |
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CG 30/4885PIK3CD 29/4885PIK3CA 24/4885 |
| US-20200338083-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CG 45/4885PIK3CD 23/4885PIK3CA 18/4885 |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | ROCK1, ADCK1, MAP3K20 | PIK3CG 180/4885PIK3CD 245/4885PIK3CA 163/4885 |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CG 3107/4885PIK3CD 2515/4885PIK3CA 1228/4885 |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | PIK3CG 5/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20220241287-A1 | COMBINATION THERAPIES | FLT3, TLR3, BTK | PIK3CG 216/4885PIK3CD 161/4885PIK3CA 100/4885 |
| US-20170143737-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | PIK3CG 56/4885PIK3CD 13/4885PIK3CA 30/4885 |
| US-20240317763-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
| US-20220125794-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CG 30/4885PIK3CD 29/4885PIK3CA 24/4885 |
| US-20150320754-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CG 45/4885PIK3CD 23/4885PIK3CA 18/4885 |
| US-20210113584-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
| US-11944631-B2 | Combination therapies | BCL2, BAK1, BCL3 | PIK3CG 30/4885PIK3CD 29/4885PIK3CA 24/4885 |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CG 8/4885PIK3CD 5/4885PIK3CA 10/4885 |
| US-20170348314-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CG 45/4885PIK3CD 23/4885PIK3CA 18/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CG 1894/4885PIK3CD 1353/4885PIK3CA 426/4885 |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | CXCR3, MTOR, CX3CR1 | PIK3CG 281/4885PIK3CD 360/4885PIK3CA 395/4885 |
| US-10160761-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20190185477-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CG 3569/4885PIK3CD 2996/4885PIK3CA 2438/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIK3CG 3107/4885PIK3CD 2515/4885PIK3CA 1228/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CG 5/4885PIK3CD 6/4885PIK3CA 9/4885 |
| US-20190216816-A1 | COMBINATION THERAPIES | FLT3, TLR3, BTK | PIK3CG 216/4885PIK3CD 161/4885PIK3CA 100/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | TFEB, SQSTM1, ULK1 | PIK3CG 198/4885PIK3CD 225/4885PIK3CA 195/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | PIK3CG 470/4885PIK3CD 336/4885PIK3CA 70/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-10857156-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | PIK3CG 2706/4885PIK3CD 3305/4885PIK3CA 3408/4885 |
| US-20110166149-A1 | PTERIDINE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | PRKCH, DTYMK, PLK1 | PIK3CG 142/4885PIK3CD 115/4885PIK3CA 171/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | PIK3CG 4002/4885PIK3CD 4384/4885PIK3CA 3485/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | PIK3CG 4202/4885PIK3CD 3852/4885PIK3CA 2400/4885 |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-11247995-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PIK3CG 9/4885PIK3CD 3/4885PIK3CA 1/4885 |
| US-10934528-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | PIK3CG 1390/4885PIK3CD 1534/4885PIK3CA 2007/4885 |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | PIK3CG 1390/4885PIK3CD 1534/4885PIK3CA 2007/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PIK3CG 2394/4885PIK3CD 2143/4885PIK3CA 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.